Sartorius Viral Vectors Platform

Single-Use Technologies and Associated Services to Address the Process Development and Productions Needs of Manufacturers of Viral Vectors

Sartorius technologies are ideally suited for the production of viral vaccines, vectors and gene therapies. They allow end-to-end, single-use processing of viruses from process development through to commercial manufacturing at the 2000 L-scale. Manufacturers of virus-related products are benefiting from our unique upstream and downstream technologies, analytics and services including our process development consultancy, cost modelling and process engineering capabilities.

Gene therapy has become one of the most rapidly evolving and promising fields in regenerative medicine and has a wide range of potential applications, such as the treatment of hereditary genetic disorders, cancer and infectious diseases. Gene therapy mainly encompasses the use of a viral vector to introduce an intact gene, either directly into the patient (in vivo) or indirectly via transduction of cells before infusion into the patient (ex vivo), to reconstitute or modify a harmful gene variant.

The growing number of viral vectors used as clinical therapeutics will require scalable commercial upstream and downstream processes to be developed and optimized to ensure that critical quality attributes (CQAs) are retained.